# ReForm Biologics and MilliporeSigma sign licensing agreement for excipient development

ReForm Biologics and MilliporeSigma (the Life Science business of Merck KGaA) announced a global license agreement to commercialize ReForm's proprietary excipients for biotherapeutic formulations. MilliporeSigma will fund R&D and handle commercialization and GMP manufacturing.

- Type: Contract
- Announced: 2020-02-10
- Status: announced
- Products: excipients for biotherapeutic formulations
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Merck KGaA](https://endata.com/companies/1393.md) (partner)
- [MilliporeSigma](https://endata.com/companies/7341.md) (partner)
- [ReForm Biologics](https://endata.com/companies/45158.md) (partner)

## Sources

- [pharmaceuticaldaily.com](https://pharmaceuticaldaily.com/reform-biologics-and-milliporesigma-announce-a-licensing-agreement-for-excipient-development-and-commercialization/), 2020-02-10: "MilliporeSigma is a global leader in providing pharmaceutical excipients for biologic formulation."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.